Back
 JCT  Vol.5 No.2 , February 2014
Investigation of Combining Serum Tumor Biomarkers and Clinical Features for Elderly Lung Cancer Diagnosis and Classification
Abstract: To evaluate the diagnosis model of serum tumor biomarker and several clinical features diagnose and classification for lung cancer, the solid protein chip technology (C-12) was used to detect the biomarkers of SF, CEA, CA242, NSE, CA125, CA19-9 and CA15-3 in serum and several clinical features of tumors and benign disease in elderly lung cancer patients were collected. Set up a discriminating analysis as a function diagnostic model in clinical elderly lung cancer diagnosis and sub-type discrimination. In combination of 2 obvious clinical indicators and 2 serum markers, it is possible to provide a diagnosis tool for lung cancer. With the help of mathematic model, it is promising to reduce the misjudgment risk based on the previous experience and therefore establish a reliable diagnosing function. This model is simple, cost-effective and easy to adapt in practice, and can also be used in screening of large population.
Cite this paper: Y. Tian, M. Yu, L. Sun, X. Ren, W. Liang, W. Shang, S. Huo, L. Liu, Y. Ren, H. Wen, Z. Yang, S. Wei and C. Wang, "Investigation of Combining Serum Tumor Biomarkers and Clinical Features for Elderly Lung Cancer Diagnosis and Classification," Journal of Cancer Therapy, Vol. 5 No. 2, 2014, pp. 133-140. doi: 10.4236/jct.2014.52016.
References

[1]   H. H. Lin, M. Murray, T. Cohen, et al., “Effects of Smoking and Solid-Fuel Use on COPD, Lung Cancer, and Tuberculosis in China: A Time-Based, Multiple Risk Factors, Modeling Study,” Lancet, Vol. 372, No. 9648, 2008, 1473-1483.

[2]   H. M. Zeng, R. S. Zheng, S. W. Zhang, et al., “Trend Analysis of Cancer Mortality in China between 1989 and 2008,” Chinese Journal of Clinical Oncology, Vol. 7, No. 34, 2012, pp. 525-531.

[3]   W. Q. Chen, R. S. Zheng, H. M. Zeng, et al., “Trend Analysis and Projection of Cancer Incidence in China between 1989 and 2008,” Chinese Journal of Clinical Oncology, Vol. 7, No. 34, 2012, pp. 517-524.

[4]   T. S. Mok, Y. L. Wu, S. Thongprasert, et al., “Gefitinb or Carboplatin Paclitaxel in Pulmonary Adenocarcinoma,” The New England Journal of Medicine, Vol. 361, No. 10, 2009, p. 947.
http://dx.doi.org/10.1056/NEJMoa0810699

[5]   Y. Bang, E. L. Kwak, A. Shaw, et al., “Clinical Activity of the Oral ALK Inhibitor, PF-02341066, in ALK-Positive Patients with Non-Small Cell Lung Cancer,” Journal of Clinical Oncology, Vol. 28, No, 18, 2010, p. 3.

[6]   G. V. Scagliotti, P. Parikh, J. Von Pawel, et al., “Phase Ⅲ Study Comparing Cisplatin plus Gemcitabine with Cisplatin plus Pemetrexed in Chemotherapy-Naive Patients with Advanced-Stage Non-Small-Cell Lung Cancer,” Chinese Journal of Clinical Oncology, Vol. 26, No. 21, 2008, p. 3543.
http://dx.doi.org/10.1200/JCO.2007.15.0375

[7]   A. Jemal, M. J. Thun, T. L. Rise, et al., “Annual Report to the Nation on the Status of Cancer, 1975-2005, Featuring Trends in Lung Cancer, Tobacco Use, and Tobacco Control,” Journal of the National Cancer Institute, Vol. 100, No. 23, 2008, pp.1672-1694. http://dx.doi.org/10.1093/jnci/djn389

[8]   J. A. Alberg, J. G. Ford and J. M. Samet, “Epidemiology of Lung Cancer,” Chest, Vol. 132, Suppl. 3, 2007, pp. 29-55. http://dx.doi.org/10.1378/chest.07-1347

[9]   I. Visintin, Z. Feng, G. Longton, et al., “Diagnostic Markers for Early Detection of Ovarian Cancer,” Clinical Cancer Research, Vol.14, 2008, pp. 1065-1072. http://dx.doi.org/10.1158/1078-0432.CCR-07-1569

[10]   J. Zhou, L. Yu, X. Gao, et al., “Plasma MicroRNA Panel to Diagnose Hepatitis B Virus-Related Hepatocellular Carcinoma,” Journal of Clinical Oncology, Vol. 38, 2011, p. 2697.

[11]   I. Visintin, Z. D. Feng, G. Longton, et al., “Diagnostic Markers for Early Detection of Ovarian Cancer,” Clinical Cancer Research, Vol. 14, No. 4, 2008, pp. 1065-1072. http://dx.doi.org/10.1158/1078-0432. CCR-07-1569

[12]   M. Fiorentino, E. Capizzi and M. Loda, “Blood and Tissue Biomarkers in Prostate Cancer: State of the Art,” Urologic Clinics of North America, Vol. 37, No. 1, 2010, pp. 131-141. http://dx.doi.org/10.1016/ j.ucl.2009.11.006

[13]   NCCN Guidelines for Patients, 2012. Http://www.nccn.com

[14]   T. R. Asmis, K. Ding, L. Seymour, et al., “Age and Comorbidity as Independent Prognostic Factors in the Treatment of Non-Small-Cell Lung Cancer: A Review of National Cancer Institute of Canada Clinical Trials Group Trial,” Journal of Clinical Oncology, Vol. 26, No. 1, 2008, pp. 54-59.
http://dx.doi.org/10.1200/JCO.2007.12.8322

[15]   M. Okada, W. Nishio, T. Skaamoto, et al., “Effect of Histologic Type and Smoking Status on Interpretation of Serum Carcinoembryonic Antigen Value in Non-Small Cell Lung Carcinoma,” The Annals of Thoracic Surgery, Vol. 78, No. 3, 2004, p. 1004. http://dx.doi.org/10.1016/j.athoracsur. 2004.03.019

[16]   M. Tomita, Y. Matsuzaki, M. Ham, et al., “Relationship between Serum Carcinoembryoinc Antigen Level and T Status in Non-Small Cell Lung Cancer,” Anticancer Research, Vol. 5B, 2006, p. 845.

[17]   R. Kawachi, Y. Kazato, H. Kei, et al., “Clinical Significance of Preoperative Carcincembryonic Antigen Level for Clinical Stage I Non-Small Cell Lung Cancer: Can Preoperative Carcinoembryonic Antigen Level Predict Pathological Stage?” Interactive Cardio Vasc Thoracic Surgery, Vol. 9, No. 2, 2009, p. 199.

[18]   K. Hotta, K. Kiura, M. Tabata, et al., “Role of Early Serial Change in Serum Carcinoembryonic Antigen Levels as a Predictive Marker for Radiological Response to Gefitinib in Japanese Patients with Non-Small Cell Lung Cancer,” Anticancer Research, Vol. 27, No, 3B, 2007, p. 1737.

[19]   C. H. Chiu, Y. N. Shih, S. M. Tsai, et al., “Serum Carcinoembryonic Antigen as a Predictive Marker for Sensitivity to Gefitinib in Advanced Non-Small Cell Lung Cancer,” Lung Cancer, Vol. 57, No. 2, 2007, p. 213. http://dx.doi.org/10.1016/j.lungcan.2007.02.016

[20]   H. J. Sung and J. Y. Cho, “Biomarkers for the Lung Cancer Diagnosis and Their Advances in Proteomics,” BMB Reports, Vol. 41, No. 9, 2008, pp. 615-625. http://dx.doi.org/10.5483/BMBRep. 2008.41.9.615

[21]   S. R. Weinberger, E. A. Damasso and E. T. Fung, “Current Achievements Using Protein Chip Array Technology,” Current Opinion in Chemical Biology, Vol. 6, No. 1, 2002, pp. 86-91.
http://dx.doi.org/10.1016/S1367-5931(01)00282-4

[22]   M. R. Spitz, W. K. Hong, C. H. Amos, et al., “A risk Model for Prediction of Lung Cancer,” Journal of the National Cancer Institute, Vol. 99, No. 7, 2007, pp. 15-726. http://dx.doi.org/10.1093/jnci/djk153

[23]   S. Cedres, I. Nunez, M. Longo, et al., “Serum Tumor Markers CEA, CYFRA21-1, and CA-125 Are Associated With Worse Prognosis In Advanced Non-Small-Cell Lung Cancer (NSCLC),” Clinical Lung Cancer, Vol. 3, No. 12, 2011, pp. 172-179. http://dx.doi.org/10.1016/j.cllc.2011.03.019

[24]   S. Holdenrieder, J. Pawel, E. Dankelmann, et al., “Nucleosomes, ProGRP, NSE, CYFRA21-1, and CEA in Monitoring First-Line Chemotherapy of Small Cell Lung Cancer,” Clinical Cancer Research, Vol. 14, 2008, pp. 7813-7821. http://dx.doi.org/10.1158/1078-0432.CCR-08-0678

[25]   N. Kosaka, H. Iguchi and T. Ochiya, “Circulating microRNA in Body Fluid: A New Potential Biomarker for Cancer Diagnosis and Prognosis,” Cancer Science, Vol. 101, No. 10, 2010, pp. 2087-2092. http://dx.doi.org/10.1111/j.1349-7006.2010.01650.x

[26]   M. F. Akay, “Support Vector Machines Combined with Feature Selection for Breast Cancer Diagnosis,” Expert Systems with Applications, Vol. 2, No. 36, 2009, pp. 3240-3247. http://dx.doi.org/10.1016/ j.eswa.2008.01.009

[27]   E. F. PatzJr, M. J. Campa, E. B. Gottlin, et al., “Panel of Serum Biomarkers for the Diagnosis of Lung Cancer,” Journal of Clinical Oncology, Vol. 25, No. 35, 2007, pp. 5578-5583. http://dx.doi.org/10. 1200/JCO.2007.13.5392

 
 
Top